Neuroscience and accelerator mass spectrometry

Magnus Palmblad, Bruce A. Buchholz, Darren J. Hillegonds, John S. Vogel

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Accelerator mass spectrometry (AMS) is a mass spectrometric method for quantifying rare isotopes. It has had a great impact in geochronology and archaeology and is now being applied in biomedicine. AMS measures radioisotopes such as 3H, 14C, 26Al, 36Cl and 41Ca, with zepto- or attomole sensitivity and high precision and throughput, allowing safe human pharmacokinetic studies involving microgram doses, agents having low bioavailability or toxicology studies where administered doses must be kept low (<1 μg kg-1). It is used to study long-term pharmacokinetics, to identify biomolecular interactions, to determine chronic and low-dose effects or molecular targets of neurotoxic substances, to quantify transport across the blood-brain barrier and to resolve molecular turnover rates in the human brain on the time-scale of decades. We review here how AMS is applied in neurotoxicology and neuroscience.

Original languageEnglish (US)
Pages (from-to)154-159
Number of pages6
JournalJournal of Mass Spectrometry
Volume40
Issue number2
DOIs
StatePublished - Feb 2005
Externally publishedYes

Fingerprint

neurology
Neurosciences
Particle accelerators
Mass spectrometry
Mass Spectrometry
accelerators
Pharmacokinetics
mass spectroscopy
dosage
Archaeology
Geochronology
toxicology
blood-brain barrier
archaeology
bioavailability
geochronology
Blood-Brain Barrier
Radioisotopes
Isotopes
Toxicology

Keywords

  • Accelerator mass spectrometry
  • Alzheimer's disease
  • Carbon-14
  • Diisopropyl fluorophosphate
  • Radiocarbon

ASJC Scopus subject areas

  • Organic Chemistry
  • Spectroscopy
  • Biophysics

Cite this

Palmblad, M., Buchholz, B. A., Hillegonds, D. J., & Vogel, J. S. (2005). Neuroscience and accelerator mass spectrometry. Journal of Mass Spectrometry, 40(2), 154-159. https://doi.org/10.1002/jms.734

Neuroscience and accelerator mass spectrometry. / Palmblad, Magnus; Buchholz, Bruce A.; Hillegonds, Darren J.; Vogel, John S.

In: Journal of Mass Spectrometry, Vol. 40, No. 2, 02.2005, p. 154-159.

Research output: Contribution to journalArticle

Palmblad, M, Buchholz, BA, Hillegonds, DJ & Vogel, JS 2005, 'Neuroscience and accelerator mass spectrometry', Journal of Mass Spectrometry, vol. 40, no. 2, pp. 154-159. https://doi.org/10.1002/jms.734
Palmblad M, Buchholz BA, Hillegonds DJ, Vogel JS. Neuroscience and accelerator mass spectrometry. Journal of Mass Spectrometry. 2005 Feb;40(2):154-159. https://doi.org/10.1002/jms.734
Palmblad, Magnus ; Buchholz, Bruce A. ; Hillegonds, Darren J. ; Vogel, John S. / Neuroscience and accelerator mass spectrometry. In: Journal of Mass Spectrometry. 2005 ; Vol. 40, No. 2. pp. 154-159.
@article{ebf89776273d4705810165bebd3ac786,
title = "Neuroscience and accelerator mass spectrometry",
abstract = "Accelerator mass spectrometry (AMS) is a mass spectrometric method for quantifying rare isotopes. It has had a great impact in geochronology and archaeology and is now being applied in biomedicine. AMS measures radioisotopes such as 3H, 14C, 26Al, 36Cl and 41Ca, with zepto- or attomole sensitivity and high precision and throughput, allowing safe human pharmacokinetic studies involving microgram doses, agents having low bioavailability or toxicology studies where administered doses must be kept low (<1 μg kg-1). It is used to study long-term pharmacokinetics, to identify biomolecular interactions, to determine chronic and low-dose effects or molecular targets of neurotoxic substances, to quantify transport across the blood-brain barrier and to resolve molecular turnover rates in the human brain on the time-scale of decades. We review here how AMS is applied in neurotoxicology and neuroscience.",
keywords = "Accelerator mass spectrometry, Alzheimer's disease, Carbon-14, Diisopropyl fluorophosphate, Radiocarbon",
author = "Magnus Palmblad and Buchholz, {Bruce A.} and Hillegonds, {Darren J.} and Vogel, {John S.}",
year = "2005",
month = "2",
doi = "10.1002/jms.734",
language = "English (US)",
volume = "40",
pages = "154--159",
journal = "Biomedical Mass Spectrometry",
issn = "1076-5174",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Neuroscience and accelerator mass spectrometry

AU - Palmblad, Magnus

AU - Buchholz, Bruce A.

AU - Hillegonds, Darren J.

AU - Vogel, John S.

PY - 2005/2

Y1 - 2005/2

N2 - Accelerator mass spectrometry (AMS) is a mass spectrometric method for quantifying rare isotopes. It has had a great impact in geochronology and archaeology and is now being applied in biomedicine. AMS measures radioisotopes such as 3H, 14C, 26Al, 36Cl and 41Ca, with zepto- or attomole sensitivity and high precision and throughput, allowing safe human pharmacokinetic studies involving microgram doses, agents having low bioavailability or toxicology studies where administered doses must be kept low (<1 μg kg-1). It is used to study long-term pharmacokinetics, to identify biomolecular interactions, to determine chronic and low-dose effects or molecular targets of neurotoxic substances, to quantify transport across the blood-brain barrier and to resolve molecular turnover rates in the human brain on the time-scale of decades. We review here how AMS is applied in neurotoxicology and neuroscience.

AB - Accelerator mass spectrometry (AMS) is a mass spectrometric method for quantifying rare isotopes. It has had a great impact in geochronology and archaeology and is now being applied in biomedicine. AMS measures radioisotopes such as 3H, 14C, 26Al, 36Cl and 41Ca, with zepto- or attomole sensitivity and high precision and throughput, allowing safe human pharmacokinetic studies involving microgram doses, agents having low bioavailability or toxicology studies where administered doses must be kept low (<1 μg kg-1). It is used to study long-term pharmacokinetics, to identify biomolecular interactions, to determine chronic and low-dose effects or molecular targets of neurotoxic substances, to quantify transport across the blood-brain barrier and to resolve molecular turnover rates in the human brain on the time-scale of decades. We review here how AMS is applied in neurotoxicology and neuroscience.

KW - Accelerator mass spectrometry

KW - Alzheimer's disease

KW - Carbon-14

KW - Diisopropyl fluorophosphate

KW - Radiocarbon

UR - http://www.scopus.com/inward/record.url?scp=14744276329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14744276329&partnerID=8YFLogxK

U2 - 10.1002/jms.734

DO - 10.1002/jms.734

M3 - Article

C2 - 15706618

AN - SCOPUS:14744276329

VL - 40

SP - 154

EP - 159

JO - Biomedical Mass Spectrometry

JF - Biomedical Mass Spectrometry

SN - 1076-5174

IS - 2

ER -